Abstract
Amplification of the HER2/neu gene occurs in approximately 20-25% of invasive breast cancers and is associated with poor patient outcome. The development of trastuzumab, a humanized monoclonal antibody that binds to the extracellular domain of HER2, has led to a significant improvement in outcomes of patients with HER2-positive breast cancer. However, many patients with HER2- positive metastatic breast cancer do not respond to trastuzumab, or eventually become resistant to it. In addition, approximately 15% of patients treated with trastuzumab-based therapy in the adjuvant setting relapse. In this review, we discuss the mechanisms of antitumor activity of trastuzumab, potential mechanisms contributing to its resistance, and novel therapeutic agents that may provide a means to overcome trastuzumab resistance.
Anti-Cancer Agents in Medicinal Chemistry
Title: Mechanisms of Trastuzumab Resistance in Breast Cancer
Volume: 9 Issue: 3
Author(s): Sara M. Tolaney and Ian E. Krop
Affiliation:
Abstract: Amplification of the HER2/neu gene occurs in approximately 20-25% of invasive breast cancers and is associated with poor patient outcome. The development of trastuzumab, a humanized monoclonal antibody that binds to the extracellular domain of HER2, has led to a significant improvement in outcomes of patients with HER2-positive breast cancer. However, many patients with HER2- positive metastatic breast cancer do not respond to trastuzumab, or eventually become resistant to it. In addition, approximately 15% of patients treated with trastuzumab-based therapy in the adjuvant setting relapse. In this review, we discuss the mechanisms of antitumor activity of trastuzumab, potential mechanisms contributing to its resistance, and novel therapeutic agents that may provide a means to overcome trastuzumab resistance.
Export Options
About this article
Cite this article as:
Tolaney M. Sara and Krop E. Ian, Mechanisms of Trastuzumab Resistance in Breast Cancer, Anti-Cancer Agents in Medicinal Chemistry 2009; 9 (3) . https://dx.doi.org/10.2174/1871520610909030348
DOI https://dx.doi.org/10.2174/1871520610909030348 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Multi-Class Breast Cancer Classification Using Ensemble of Pretrained models and Transfer Learning
Current Medical Imaging New Approaches With Natural Product Drugs for Overcoming Multidrug Resistance in Cancer
Current Pharmaceutical Design The Neuropeptide Systems and their Potential Role in the Treatment of Mammalian Retinal Ischemia: A Developing Story
Current Neuropharmacology Preparation and Characterization of a Heterogeneous Catalyst from Water Hyacinth (Eichhornia crassipes): Catalytic Application in the Synthesis of bis(indolyl)methanes and bis(pyrrolyl) methanes Under Solvent Free Condition
Current Catalysis Ultrasound-Based Multimodal Molecular Imaging and Functional Ultrasound Contrast Agents
Current Pharmaceutical Design Cytochrome P450-Activated Prodrugs: Targeted Drug Delivery
Current Medicinal Chemistry Data-driven Approach to Detect and Predict Adverse Drug Reactions
Current Pharmaceutical Design Antisense Oligonucleotides as an Innovative Therapeutic Strategy in the Treatment of High-Grade Gliomas
Recent Patents on CNS Drug Discovery (Discontinued) Preface
Current Pharmaceutical Design Editorial (Thematic Issue: Metabolic Disorders, Drug Development, Drug Design and Biomarkers)
Current Pharmaceutical Design Genomic and Epigenetic Complexity of the FOXF1 Locus in 16q24.1: Implications for Development and Disease
Current Genomics The Potential of Statins for Individualized Colorectal Cancer Chemoprevention
Current Drug Targets Trafficking of Neuronal Two Pore Domain Potassium Channels
Current Neuropharmacology Development of Multifunctional Nanoparticles for Targeted Drug Delivery and Noninvasive Imaging of Therapeutic Effect
Current Drug Discovery Technologies Pharmacogenetics of Drug Transporters and Its Impact on the Pharmacotherapy
Current Topics in Medicinal Chemistry Development of Colon Specific Microspheres of Flurbiprofen for Inflammatory Bowel Disease
Current Drug Delivery Antisynthetase Syndrome: A Review of Etiopathogenesis, Diagnosis and Management
Current Medicinal Chemistry The Human OncoBiome Database: A Database of Cancer Microbiome Datasets
Current Bioinformatics Targeting Sphingosine-1-Phosphate Receptors in Cancer
Anti-Cancer Agents in Medicinal Chemistry The Cancer Preventive Effects of Edible Mushrooms
Anti-Cancer Agents in Medicinal Chemistry